ArticleNanotheranostics2018
Functionalized MoS
Article in Nanotheranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 43 citations in OpenAlex.
- Multifunctional nanozymes based on MoS₂ for synergistic catalytic activity and cancer photothermal therapy.Nanomedicine (London, England) · 2025Review
- Potential and Progress of 2D Materials in Photomedicine for Cancer Treatment.ACS applied bio materials · 2023Review
- An Efficient, Short Stimulus PANC-1 Cancer Cell Ablation and Electrothermal Therapy Driven by Hydrophobic Interactions.Pharmaceutics · 2022Article
- Nano-bio interactions of 2D molybdenum disulfide.Advanced drug delivery reviews · 2022Review
- MoSBioactive materials · 2021Review
- DNA Nanostructures and DNA-Functionalized Nanoparticles for Cancer Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Update on current pancreatic treatments: from molecular pathways to treatment.Journal of Cancer · 2019Review
- Non-invasiveTheranostics · 2019Article
- Two-Dimensional Nanosheet-Based Photonic Nanomedicine for Combined Gene and Photothermal Therapy.Frontiers in pharmacology · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transition metal dichalcogenides (TMDCs) are categorized as novel two-dimensional (2D) nanomaterials with unique physical and chemical properties, bearing varied applications in medical and materials sciences. However, only a few works report the application of TMDCs for gene therapy in cancer treatment. Here, we engineer a multi-gene delivery system based on functionalized monolayer MoS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.